MRK ▼ -2.4% - Merck & Co., Inc.
$MRK Sacituzumab Tirumotecan (Sac-TMT) Reduced the Risk of Death by 32% and the Risk of Disease Progression or Death by 41% Compared to Chemotherapy in Certain Patients With Advanced or Recurrent Endometrial Cancer
26-OCT-2026 11:30 AM ET
Share this post
More filings for $MRK
MRK ▲ +0.6% - Merck & Co., Inc.Nov 13, 2026MRK ▲ +0.6% - Merck & Co., Inc.Nov 13, 2026MRK ▲ +1.2% - Merck & Co., Inc.Nov 9, 2026MRK ▲ +0.9% - Merck & Co., Inc.Nov 9, 2026MRK ▼ -0.5% - Merck & Co., Inc.Nov 3, 2026MRK ▲ +2.8% - Merck & Co., Inc.Oct 29, 2026
View full $MRK filing history →💬 Comments
Loading comments…
Leave a comment